Ireland· IE-PA-EU/1/14/945/007-008
IMBRUVICA 140 mg film-coated tablets
A ibrutinib product containing ibrutinib, registered in Ireland by Janssen-Cilag International NV.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Ibrutinib
- Manufacturer
- Janssen-Cilag International NV
- Country
- Ireland (IE)
- ATC code
- L01XE27
- ATC class
- Ibrutinib
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/14/945/007-008
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
370 interactions on record for ibrutinib.
Graded by severity as the source publishes them — 189 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ibrutinib · interactions on record
370 records
- 189 severe
- 177 moderate
- 4 minor
Most severe, free to view
- AprepitantA04AD12severe
- LinseedA06AC05severe
- LonafarnibA16AX20severe
- DicoumarolB01AA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ibrutinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaIMBRUVICAJanssen-Cilag International N.V., Beerse
- SwitzerlandImbruvica
- SpainIMBRUVICA 140 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
- FinlandImbruvicaJanssen-Cilag International NV
- FranceIMBRUVICA 140 mg, comprimé pelliculéJANSSEN CILAG INTERNATIONAL NV
- IcelandIMBRUVICAJanssen-Cilag International NV*
- NetherlandsIMBRUVICA 140 mg filmomhulde tablettenJanssen-Cilag International NV
- NorwayImbruvicaJanssen-Cilag International N.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imbruvica
- Liechtenstein · Imbruvica
- Norway · Imbruvica
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/503e96c1-cc95-4ce7-8a95-c63a2c35f270 GET /v1/drugs/503e96c1-cc95-4ce7-8a95-c63a2c35f270?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01XE27"
],
"strength": null,
"pa_number": "EU/1/14/945/007-008",
"substances": [
"Ibrutinib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ibrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.